Top Markets
#1 Black Phoenix Black Phoenix +21,511.25%
#2 Nesa Nesa +681.29%
#3 Ontology Gas Ontology Gas +69.86%
#4 Kinesis Silver Kinesis Silver +55.34%
#5 Lisk Lisk +26.09%
#6 QuantixAI QuantixAI +23.07%
#7 EXOD EXOD +22.78%
#8 Biconomy Biconomy +21.72%
#9 SAFEcoin SAFEcoin +21.21%
#10 BNB Attestation Service BNB Attestation Service +20.90%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Camurus AB Camurus AB

Camurus AB

CAMX
Rank in Stocks #4181
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Share Price
$68.19
Market Cap
$4.06B
Change (1 day)
-0.73%
Change (1 year)
-7.20%
Country
SE
Trade Camurus AB (CAMX)

Category

Healthcare
Number of shares outstanding for Camurus AB (CAMX)
Number of shares outstanding as of August 2026: 0
According to Camurus AB latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Camurus AB (CAMX) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH